MYD88 mutations have been reported to be pathogenetically relevant in some cutaneous diffuse large B-cell lymphomas, leg type, and curiously seem to be mutually exclusive from other cancer-promoting mutations that activate the NF-κB pathway including BRAF, PIK3, or STAT3. This evidence concerns the gene BRAF and diffuse large B-cell lymphoma.